Related Articles
Synergistic interaction between MEK inhibitor and gefitinib in EGFR‑TKI‑resistant human lung cancer cells
Placenta‑specific 8 is a potential novel target for osimertinib resistance in non‑small cell lung cancer
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition
Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations